Clinuvel in the Community

The Clinuvel team is committed to making a lasting difference to the communities involved with our clinical program. We work closely with patients, physicians and the broader community to help:

  • improve access to treatment and educational resources;
  • enhance dialogue between specialist academic and physician centres;
  • facilitate connections between patients and physicians; and
  • educate the public on the impact of various diseases, including EPP and vitiligo.

Clinuvel Blog Posts

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Clinuvel Spotlight

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...

Read more